Literature DB >> 18779731

Patchy distribution of pathologic abnormalities in autoimmune pancreatitis: implications for preoperative diagnosis.

Vishal S Chandan1, Christine Iacobuzio-Donahue, Susan C Abraham.   

Abstract

Autoimmune pancreatitis (AIP) is a distinctive form of chronic pancreatitis that can mimic pancreatic carcinoma. In the past, AIP accounted for up to 27% of Whipple resections performed for suspected adenocarcinoma. More recently, with increased awareness of AIP and reports of its steroid responsiveness, tru-cut needle biopsies are increasingly used as an aid in preoperative diagnosis. We noticed a distinctive patchy distribution to the pathologic abnormalities in many cases of resected AIP that could potentially interfere with preoperative diagnosis by needle biopsy. We studied 39 pancreatic resections with AIP, defined by the following triad of features: (1) lymphoplasmacytic infiltrates around ducts, (2) acinar lymphoplasmacytic inflammation with atrophy and fibrosis, and (3) obliterative phlebitis. Criteria for inclusion in the study included either submission of the entire resection specimen (n=21) or extensive histologic sampling (n=18) defined as submission of > or =10 sections. We reviewed all hematoxylin and eosin-stained sections and (1) mapped areas of sparing and involvement by AIP, (2) classified the AIP as lobulocentric, ductocentric, or mixed, and (3) tabulated numbers of immunoglobulin (Ig) G4+ plasma cells in areas of involvement and sparing. To be included as an area of sparing, both duct and acinar parenchyma had to be free of lymphoplasmacytic inflammation, and the focus had to be at least 0.5 cm in diameter. Our results demonstrate a high prevalence of patchiness in AIP. Thirty-two (82%) specimens had areas of sparing (mean of 22% of each specimen spared, range 0.8% to 80%). The largest focus of uninvolved pancreas varied from 0.5 to 8.8 cm(2) (mean: 1.8 cm(2)). In the remaining 7 (18%) cases, the changes of AIP were diffuse, with involvement of the entire submitted specimen. Number of IgG4+ plasma cells correlated highly with areas of involvement versus sparing by AIP; there were > or =5 IgG4+ plasma cells/20x field in 34 of 35 (97%) involved foci, but in only 1 of 26 (4%) histologically uninvolved foci (P<0.001). Classification as lobulocentric AIP (n=11), ductocentric AIP (n=15), and mixed AIP (n=12) did not correlate with extent of patchiness (P=0.92) or with the volume of spared parenchyma (P=1.0). These results demonstrate patchy involvement by AIP in a majority of resected pancreata. In specimens containing large areas of uninvolved parenchyma, this raises the potential for underdiagnosis by tru-cut biopsy. In patients with radiologic and serologic features (eg, elevated serum IgG4 level) suspicious for AIP, this potential pitfall in pathologic diagnosis should be considered before proceeding to surgery. IgG4 immunostaining of apparently negative biopsies may be helpful, but only in a small minority of cases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18779731     DOI: 10.1097/PAS.0b013e318181f9ca

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

1.  Characteristic magnetic resonance features of focal autoimmune pancreatitis useful for differentiation from pancreatic cancer.

Authors:  Yukiko Sugiyama; Yasunari Fujinaga; Masumi Kadoya; Kazuhiko Ueda; Masahiro Kurozumi; Hideaki Hamano; Shigeyuki Kawa
Journal:  Jpn J Radiol       Date:  2012-01-12       Impact factor: 2.374

Review 2.  Autoimmune pancreatitis and IgG4-related systemic diseases.

Authors:  Lizhi Zhang; Thomas C Smyrk
Journal:  Int J Clin Exp Pathol       Date:  2010-05-25

3.  Utility of pancreatography for diagnosing autoimmune pancreatitis.

Authors:  Kensuke Takuma; Terumi Kamisawa; Taku Tabata; Yoshihiko Inaba; Naoto Egawa; Yoshinori Igarashi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

4.  The similarity of Type 1 autoimmune pancreatitis to pancreatic ductal adenocarcinoma with significant IgG4-positive plasma cell infiltration.

Authors:  Yuri Fukui; Kazushige Uchida; Kimi Sumimoto; Takeo Kusuda; Hideaki Miyoshi; Masanori Koyabu; Tsukasa Ikeura; Yutaku Sakaguchi; Masaaki Shimatani; Toshiro Fukui; Mitsunobu Matsushita; Makoto Takaoka; Akiyoshi Nishio; Nobuaki Shikata; Noriko Sakaida; Yoshiko Uemura; Sohei Satoi; A-Hon Kwon; Kazuichi Okazaki
Journal:  J Gastroenterol       Date:  2012-10-05       Impact factor: 7.527

5.  Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process.

Authors:  J-Matthias Löhr; Ralf Faissner; Dirk Koczan; Peter Bewerunge; Claudio Bassi; Benedikt Brors; Roland Eils; Luca Frulloni; Anette Funk; Walter Halangk; Ralf Jesenofsky; Ralf Jesnowski; Lars Kaderali; Jörg Kleeff; Burkhard Krüger; Markus M Lerch; Ralf Lösel; Mauro Magnani; Michael Neumaier; Stephanie Nittka; Miklós Sahin-Tóth; Julian Sänger; Sonja Serafini; Martina Schnölzer; Hermann-Josef Thierse; Silke Wandschneider; Giuseppe Zamboni; Günter Klöppel
Journal:  Am J Gastroenterol       Date:  2010-04-20       Impact factor: 10.864

Review 6.  IgG4-related sclerosing disease, an emerging entity: a review of a multi-system disease.

Authors:  Mukul Divatia; Sun A Kim; Jae Y Ro
Journal:  Yonsei Med J       Date:  2012-01       Impact factor: 2.759

7.  Immunoglobulin G4-related sclerosing cholecystitis presenting as gallbladder cancer: a case report.

Authors:  Kodai Takahashi; Hideto Ito; Toshio Katsube; Ayaka Tsuboi; Masatoshi Hashimoto; Emi Ota; Kazuhito Mita; Hideki Asakawa; Takashi Hayashi; Keiichi Fujino; Sigeru Okamoto
Journal:  Surg Case Rep       Date:  2015-12-03

8.  Evaluating IPMN and pancreatic carcinoma utilizing quantitative histopathology.

Authors:  Evan S Glazer; Hao Helen Zhang; Kimberly A Hill; Charmi Patel; Stephanie T Kha; Michael L Yozwiak; Hubert Bartels; Nellie N Nafissi; Joseph C Watkins; David S Alberts; Robert S Krouse
Journal:  Cancer Med       Date:  2016-09-26       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.